Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
zidovudine and lamivudine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| zidovudine and lamivudine (Combivir®) | DRUG | - |
| emtricitabine and tenofovir DF | DRUG | - |
Inclusion Criteria: 1. Patients of either sex aged \> 18 years. 2. HIV positive. 3. Stable antiretroviral therapy consisting of efavirenz (EFV) given with Combivir® or zidovudine (AZT) + lamivudine (3TC) for at least 6 months. 4. Patients with viral loads \< 50 copies/ml on last 2 consecutive tests...
Top 20 of 28 competitors
Zidovudine and lamivudine is a combination of two small molecule antiretroviral drugs used for the treatment of HIV Infections. It is being developed by Gilead Sciences, Inc. (NASDAQ: GILD) and is currently in Phase 3 clinical development. The drug is intended for adult patients, as the clinical trial enrolled individuals aged 18 years and older.
Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that target the HIV reverse transcriptase enzyme. By inhibiting this enzyme, the drugs interfere with the replication of the HIV virus, reducing viral load in patients with HIV Infections. This mechanism is the basis for their use in antiretroviral therapy.
Zidovudine and lamivudine is developed by Gilead Sciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol GILD. Gilead Sciences is conducting clinical trials to evaluate the safety and efficacy of this combination therapy for the treatment of HIV Infections.
Zidovudine and lamivudine is in Phase 3 clinical development for the treatment of HIV Infections. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial, known as SWEET, has been completed, and the drug is being evaluated for its efficacy and safety in this late-stage study.
Zidovudine and lamivudine has been studied in one Phase 3 clinical trial with the identifier NCT00323544, titled "SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection." This completed trial enrolled 220 participants in the United Kingdom and was an uncontrolled, randomized study involving adult patients with HIV Infections.